Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Honeywell International Inc (HON) vs Viatris Inc (VTRS) Price & Performance

Honeywell International IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Honeywell International Inc vs Viatris Inc — how do they compare? Honeywell International Inc trades at $206.77 (market cap $65.48B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Honeywell International Inc is far larger — about 3.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Viatris Inc for 57 Days on average.

HONVTRS
Market Cap
$65.48B$20.03B
Volume
2,047,78214,109,977
Sector
IndustrialsHealth
52-Week High
$248.79$18.27
52-Week Low
$188.14$9.74
Typical Hold Time
90 Days57 Days
Enterprise Value
$90.27B$32.15B
Dividend Yield
1.36%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Honeywell International Inc

Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 8 and robust profitability margins. The company has beaten earnings estimates for three consecutive quarters and maintains a 66.7% analyst buy rating with a $259.25 consensus price target. Recent corporate developments include a $300 million refinery project win and quarterly dividend payments of $0.70 per share.

The outlook remains positive given HON's earnings momentum and strategic focus on automation post-spinoff, though technical weakness and rising debt-to-asset ratios pose near-term risks. Wall Street optimism is supported by strong profitability metrics and recent contract wins, while investors should monitor execution of the company's transformation strategy and macroeconomic pressures on industrial demand.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HON
56% Buy44% Sell
Avg holding period · 90 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Honeywell International Inc

Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.

Read more on HON →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →